Novartis to Boost Development of Anti-Malaria, Tropical-Disease Drugs
23 Junho 2022 - 3:31AM
Dow Jones News
By Joshua Kirby
Novartis AG said Thursday that it will invest $250 million in
research against malaria and neglected tropical diseases, or
NTDs.
As part of the five-year commitment, the Swiss drugmaker will
invest $100 million to advance research and development of its NTS
program, focusing on novel drug candidates for four disease, namely
Chagas, visceral leishmaniasis, dengue fever and Cryptosporidium,
which are all at varying stages of development.
Meanwhile, Novartis said it will invest $150 million to advance
three novel drug candidates against malaria. The company will
continue with activities to support the development of an optimized
formulation for neonates and infants under 5 kilograms, for whom no
treatment currently exists, Novartis said.
The investment commitment comes as Novartis endorses the Kigali
Declaration amid the 26th Commonwealth Heads of Government Meeting
in Rwanda.
The declaration aims to combat NTDs and deliver the targets set
out in the World Health Organization's NTD Roadmap 2021-30,
Novartis said.
Write to Joshua Kirby at joshua.kirby@wsj.com;
@joshualeokirby
(END) Dow Jones Newswires
June 23, 2022 02:16 ET (06:16 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025
